Pharmaceutical Active Ingredients TRIZ Cases
- MUC1-C Antisense Oligonucleotides With Lipid Nanoparticles for Cancer
Lipid nanoparticle delivery helps MUC1-C antisense oligonucleotides resist degradation, reduce tumor cell survival, and expand cancer treatment options.
- C5-Targeting Oligomeric Compounds for Lower-Cost RNA Silencing
Chemically modified oligomeric compounds use RNA interference to suppress C5 mRNA while addressing synthesis cost and off-target effects.
- Twice-Daily Fractionated Radiation for Melanoma Treatment
Twice-daily radiation fractions of about 135 cGy address melanoma’s resistance to standard therapy while limiting normal-tissue morbidity.
- Humanized YKL-40 Antibodies for Lower Immunogenicity
See how humanized YKL-40 antibodies retain human and murine binding while reducing immunogenicity for cancer therapy.
- Therapeutic Nutritional Composition for Altered Metabolic Pathways
Combining therapeutic proteins, amino acids, fats, vitamins, minerals, and probiotics addresses deficiencies while activating altered metabolic pathways.
- Organopolysiloxane Emulsion Polymerization with Acid Catalyst
Emulsifying low-volatile organopolysiloxanes enables stable emulsion polymerization, suppressing octamethylcyclotetrasiloxane formation.
- Dietary Supplement Bioavailability and Chelation Formulation
A dietary supplement formulation combining bioavailability enhancers with chelating agents to support nutrient absorption and toxin removal.